Bullish
Pfizer's TUKYSA regimen approved for HER2+ breast cancer maintenance treatment.
Pfizer's TUKYSA regimen, combined with trastuzumab and pertuzumab, has been approved by the FDA as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. This approval is based on the Phase 3 HER2CLIMB-05 trial, which demonstrated a 35.9% reduction in the risk of disease progression or death compared to placebo. Additionally, Pfizer will present 57 abstracts at IDWeek 2026, showcasing advancements in infectious disease research, including data on pneumococcal vaccines and RSV treatments.
Key points
- FDA approves TUKYSA regimen for HER2+ metastatic breast cancer maintenance.
- Pfizer to present 57 abstracts at IDWeek 2026 on infectious disease advancements.
Sources
AI-generated from public news sources. Not financial advice.
